Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: ACADIA Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.15 Estimate, Sales $278.633M Beat $276.466M Estimate

Author: Benzinga Newsdesk | November 05, 2025 05:54pm
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.15 by 75.68 percent. This is a 30 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $278.633 million which beat the analyst consensus estimate of $276.466 million by 0.78 percent. This is a 11.27 percent increase over sales of $250.401 million the same period last year.

Posted In: ACAD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist